Nektar Therapeutics

Biocon Limited

Nobex Corporation

Other

Naktar Therapeutics

Inheris Pharmaceuticals, Inc.

Jennifer A Riggs-Sauthier

Bo-Liang Deng

Wen Zhang

Timothy A Riley

Nnochiri Ekwuribe

Zhongxu Ren

Xuyuan Gu

Lin Cheng

Antoni Kozlowski

Xiaoming Shen

Samuel P McManus

Franco J Duarte

Neel Kumar Anand

Aaron S Hammons

Stephanie Allums-Donald

Michael David Bentley

Sean M Culbertson

Nnochiri N Ekwuribe

YongQi Mu

J Milton Harris

Tacey Viegas

David R Martin

Pankaj Sharma

Natalia Aurrecoechea

Donogh John Roger O'Mahony

Guy Lalonde

C Simone Jude-Fishburn

Micah Brandon Harvey

Yuan Song

Laurie A VanderVeen

Xuejun Yuan

Vijay Kumar Khatri

Michael Lixin Shen

Aleksandrs Odinecs

Timothy Andrew Riley

Hema Gursahani

Stephanie Allums

Elizabeth Malson

Samuel P Mcmanus

David Martin

Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.

Multi-arm polymeric alkanoate conjugates

Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.

Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds

The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.

Oligomer-corticosteroid conjugates

The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.

Polymer-semaxanib moiety conjugates

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Oligomer-beta blocker conjugates

The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.

Oligomer-phenothiazine conjugates

The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.

Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.

Oligomer-opioid agonist conjugates

The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

Oligomer-containing benzamide-based compounds

The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

Growing community of inventors

Raleigh, NC, United States of America

Jennifer A Riggs-Sauthier